Clearside Biomedical

Clearside Biomedical Equity

Delisted

The The Equity of Clearside Biomedical (CLSD) as of Nov 19, 2026 is -38.86 M USD. In the previous year, The Equity was -15.91 M USD — a change of 144.19% (lower).

Equity

-38.86 MUSD

YoY

144.19%

Last updated:

In 2024, Clearside Biomedical's equity was -38.86 M USD, a 144.19% increase from the -15.91 M USD equity in the previous year.

The Clearside Biomedical Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2017
21.42 M USD
Jan 1, 2018
23.62 M USD
Jan 1, 2019
11.16 M USD
Jan 1, 2020
8.76 M USD
Jan 1, 2021
37.98 M USD
Jan 1, 2022
10.61 M USD
Jan 1, 2023
-15.91 M USD
Jan 1, 2024
-38.86 M USD
The Clearside Biomedical Equity history
YEAREquityYoY
-38.86 MUSD+144.19%
-15.91 MUSD-249.97%
10.61 MUSD-72.06%
37.98 MUSD+333.56%
8.76 MUSD-21.51%
11.16 MUSD-52.75%
23.62 MUSD+10.27%
21.42 MUSD-70.11%
71.66 MUSD+572.23%
10.66 MUSD+39.90%
7.62 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clearside Biomedical Stock analysis

What does Clearside Biomedical do? Clearside Biomedical, Inc. generates revenue through the development of drug therapies for blinding eye diseases, targeting the retina, choroid, and sclera. The company’s lead product candidate, XIPERE, is a proprietary, preservative-free suspension of the corticosteroid triamcinolone acetonide administered via suprachoroidal injection. This clinical stage biopharmaceutical firm focuses on treating conditions affecting these specific eye components to restore or preserve vision. The business model relies on advancing its proprietary therapies through clinical development rather than immediate commercial sales. By concentrating on the retina, choroid, and sclera, Clearside Biomedical, Inc. addresses critical anatomical areas involved in visual health. The company operates from its headquarters in Alpharetta, Georgia, with a dedicated team supporting its research and development efforts. Financial viability is tied to the successful progression of its drug candidates, particularly XIPERE, which utilizes a unique delivery method for triamcinolone acetonide. The firm engages in the biopharmaceutical sector by developing treatments for diseases that impact the structural and functional integrity of the eye. Its strategy centers on innovation in drug formulation and administration to treat blinding conditions effectively. Clearside Biomedical is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Clearside Biomedical's Equity

Clearside Biomedical's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Clearside Biomedical's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Clearside Biomedical's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Clearside Biomedical's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Clearside Biomedical’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Clearside Biomedical stock

The Equity of Clearside Biomedical is -38.86 M USD in 2024.

The Equity of Clearside Biomedical changed from -15.91 M USD to -38.86 M USD, representing a 144.19% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Clearside Biomedical since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Clearside Biomedical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Clearside Biomedical

All Key Metrics — Clearside Biomedical